Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Pepinemab (Primary) ; Ipilimumab; Nivolumab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 13 Nov 2018 Planned End Date changed from 30 Sep 2021 to 30 Nov 2020.
- 13 Nov 2018 Planned primary completion date changed from 30 Sep 2021 to 30 Nov 2020.
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.